Kalaris Therapeutics, Inc.
KLRSNasdaqCIK 1754068HealthcareFiscal year ends Dec 31
All transactions: 1
Non-derivative transactions reported on Forms 4, newest first. Purchases and sales (codes P and S) are open-market trades; the other codes are grants, exercises, withholding and gifts. The reported price is as stated on the form, not a market price.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2023-06-27 | Gilead Sciences, Inc.10% owner | Purchase | 2,930,870 | $3.75 | $11.0m | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 26, 2026, 17:31 ET. Listed shows no prices and gives no investment advice.